William Pao

List of Publications by Year in Descending Order

160 papers	45,793 citations	92 h-index	168 g-index
168 ext. papers	50,498 ext. citations	10.9 avg, IF	7.06 L-index

#	Paper	IF	Citations
160	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. *Cancer Research*, **2017**, 77, 2990-3000	10.1	75
159	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. *Lung Cancer*, **2017**, 113, 51-58	5.9	12
158	Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. *Clinical Cancer Research*, **2016**, 22, 426-35	12.9	32
157	Biology of Lung Cancer **2016**, 912-926.e6		0
156	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. *Science Signaling*, **2016**, 9, ra33	8.8	41
155	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. *Clinical Cancer Research*, **2016**, 22, 4837-4847	12.9	168
154	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. *Cancer Research*, **2016**, 76, 305-18	10.1	60
153	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Human Molecular Genetics*, **2016**, 25, 620-9	5.6	32
152	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. *Journal of the American Medical Informatics Association: JAMIA*, **2016**, 23, 692-700	8.6	4
151	MET Exon 14 Skipping in Non-Small Cell Lung Cancer. *Oncologist*, **2016**, 21, 481-6	5.7	67
150	Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *JAMA Oncology*, **2015**, 1, 88-96	13.4	207
149	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. *Cancer Research*, **2015**, 75, 2489-500	10.1	206
148	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. *Methods*, **2015**, 83, 118-27	4.6	22
147	Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. *Cancer Discovery*, **2015**, 5, 348-50	24.4	9
146	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 542-52	6.1	26
145	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. *Cancer Informatics*, **2015**, 14, 19-31	2.4	48
144	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. *International Journal of Cancer*, **2015**, 137, 311-9	7.5	55

143	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. *Oncotarget*, **2015**, 6, 11357-68	3.3	13
142	NF-B drives acquired resistance to a novel mutant-selective EGFR inhibitor. *Oncotarget*, **2015**, 6, 42717-33	3.3	27
141	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. *Oncotarget*, **2015**, 6, 22348-60	3.3	8
140	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. *Molecular Cancer Therapeutics*, **2014**, 13, 1918-28	6.1	69
139	Beyond histology: translating tumor genotypes into clinically effective targeted therapies. *Clinical Cancer Research*, **2014**, 20, 2264-75	12.9	51
138	Anchored multiplex PCR for targeted next-generation sequencing. *Nature Medicine*, **2014**, 20, 1479-84	50.5	536
137	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. *Oncologist*, **2014**, 19, 616-22	5.7	80
136	Patterns and processes of somatic mutations in nine major cancers. *BMC Medical Genomics*, **2014**, 7, 11	3.7	47
135	Acquired resistance to TKIs in solid tumours: learning from lung cancer. *Nature Reviews Clinical Oncology*, **2014**, 11, 473-81	19.4	591
134	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. *Nature Medicine*, **2014** , 20, 1027-34	50.5	191
133	FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. *Clinical Cancer Research*, **2014**, 20, 4107-14	12.9	101
132	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. *Cancer Discovery*, **2014**, 4, 1036-45	24.4	302
131	Melanoma BRAF fusions--response. *Clinical Cancer Research*, **2014**, 20, 6632	12.9	3
130	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discovery*, **2014**, 4, 1046-61	24.4	1242
129	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1998-2006	27.4	1042
128	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. *Cell Reports*, **2014**, 7, 1824-32	10.6	19
127	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. *Genome Biology*, **2014**, 15, 489	18.3	36
126	Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. *Journal of Thoracic Oncology*, **2014**, 9, 760-8	8.9	45

125	Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. *Cancer Discovery*, **2014**, 4, 1398-405	24.4	112
124	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. *Cell Reports*, **2014**, 7, 999-1008	10.6	55
123	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. *Cancer*, **2013**, 119, 356-62	6.4	122
122	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clinical Cancer Research*, **2013**, 19, 2240-7	12.9	1655
121	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. *Respiratory Medicine*, **2013**, 107, 1755-62	4.6	20
120	Characteristics of lung cancers harboring NRAS mutations. *Clinical Cancer Research*, **2013**, 19, 2584-91	12.9	100
119	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. *Genome Medicine*, **2013**, 5, 91	14.4	125
118	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. *Journal of Clinical Oncology*, **2013**, 31, 1070-80	2.2	362
117	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E3595-604	11.5	89
116	Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. *American Journal of Roentgenology*, **2013**, 200, 475-83	5.4	27
115	Maximizing the benefits of off-target kinase inhibitor activity. *Cancer Discovery*, **2013**, 3, 138-40	24.4	9
114	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. *Cancer Discovery*, **2013**, 3, 1404-15	24.4	493
113	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. *Genome Research*, **2013**, 23, 1434-45	9.7	41
112	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. *Clinical Cancer Research*, **2013**, 19, 1894-901	12.9	83
111	Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1583-93	8.9	58
110	RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 4352-9	2.2	376
109	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. *Clinical Cancer Research*, **2012**, 18, 1947-53	12.9	140
108	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nature Genetics*, **2012**, 44, 1330-5	36.3	237

107	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*, **2012**, 150, 1107-20	32.2	1304
106	Translating genomic information into clinical medicine: lung cancer as a paradigm. *Genome Research*, **2012**, 22, 2101-8	9.7	64
105	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. *Cancer Discovery*, **2012**, 2, 922-33	24.4	528
104	ROS1 rearrangements define a unique molecular class of lung cancers. *Journal of Clinical Oncology*, **2012**, 30, 863-70	2.2	1170
103	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature Genetics*, **2012**, 44, 1104-10	36.3	919
102	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E2127-33	11.5	366
101	EGFR mutant lung cancer. *Current Topics in Microbiology and Immunology*, **2012**, 355, 59-81	3.3	5
100	New approaches to targeted therapy in lung cancer. *Proceedings of the American Thoracic Society*, **2012**, 9, 72-3		19
99	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. *Science Translational Medicine*, **2012**, 4, 120ps2	17.5	83
98	Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. *Journal of Thoracic Oncology*, **2012**, 7, 85-9	8.9	71
97	EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. *Journal of Thoracic Oncology*, **2012**, 7, 434-42	8.9	15
96	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. *Cancer Research*, **2011**, 71, 4920-31	10.1	174
95	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. *Science Translational Medicine*, **2011**, 3, 90ra59	17.5	383
94	New driver mutations in non-small-cell lung cancer. *Lancet Oncology, The*, **2011**, 12, 175-80	21.7	881
93	Molecular predictors of response to chemotherapy in non-small cell lung cancer. *Cancer Journal (Sudbury, Mass.)*, **2011**, 17, 104-13	2.2	23
92	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. *Journal of Thoracic Oncology*, **2011**, 6, 569-75	8.9	102
91	A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. *Journal of Thoracic Oncology*, **2011**, 6, 1435-7	8.9	106
90	Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. *Journal of Thoracic Oncology*, **2011**, 6, 1128-31	8.9	67

89	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9 Suppl 5, S1-32; quiz S33	7.3	195
88	Genetically informed lung cancer medicine. *Journal of Pathology*, **2011**, 223, 230-40	9.4	53
87	A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. *Journal of Molecular Diagnostics*, **2011**, 13, 74-84	5.1	155
86	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. *Molecular Pharmaceutics*, **2011**, 8, 2069-79	5.6	40
85	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. *Clinical Cancer Research*, **2011**, 17, 1169-80	12.9	467
84	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. *Clinical Cancer Research*, **2011**, 17, 5530-7	12.9	282
83	Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. *Clinical Cancer Research*, **2011**, 17, 3500-6	12.9	49
82	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. *Neuro-Oncology*, **2011**, 13, 1364-9	1	268
81	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. *Clinical Cancer Research*, **2011**, 17, 1616-22	12.9	470
80	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2011**, 29, 3825-31	2.2	229
79	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. *Clinical Cancer Research*, **2011**, 17, 2521-7	12.9	103
78	A bioinformatics workflow for variant peptide detection in shotgun proteomics. *Molecular and Cellular Proteomics*, **2011**, 10, M110.006536	7.6	73
77	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. *Clinical Cancer Research*, **2011**, 17, 6322-8	12.9	42
76	How genetically engineered mouse tumor models provide insights into human cancers. *Journal of Clinical Oncology*, **2011**, 29, 2273-81	2.2	97
75	A new target for therapy in squamous cell carcinoma of the lung. *Cancer Discovery*, **2011**, 1, 23-4	24.4	10
74	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. *PLoS ONE*, **2011**, 6, e28204	3.7	161
73	Somatic mutations of the Parkinson disease-associated gene PARK2 in glioblastoma and other human malignancies. *Nature Genetics*, **2010**, 42, 77-82	36.3	280
72	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nature Reviews Cancer*, **2010**, 10, 760-74	31.3	802

71	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. *Nucleic Acids Research*, **2010**, 38, 6985-96	20.1	36
70	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *Journal of Clinical Oncology*, **2010**, 28, 4616-20	2.2	277
69	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 357-60	2.2	615
68	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Science Translational Medicine*, **2010**, 2, 62ra93	17.5	646
67	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. *Clinical Cancer Research*, **2010**, 16, 4647-53	12.9	89
66	Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. *Clinical Cancer Research*, **2010**, 16, 5371-3	12.9	4
65	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. *Clinical Cancer Research*, **2010**, 16, 755-63	12.9	69
64	Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. *Chest*, **2010**, 137, 46-52	5.3	82
63	Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. *American Journal of Roentgenology*, **2010**, 194, 266-9	5.4	96
62	Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. *Acta Pharmacologica Sinica*, **2010**, 31, 647-8	8	11
61	Clinical Applications of Kinase Inhibitors in Solid Tumors **2010**, 615-631		1
60	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. *Journal of Thoracic Oncology*, **2010**, 5, 1048-53	8.9	68
59	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 1623-9	8.9	79
58	Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. *Journal of Thoracic Oncology*, **2010**, 5, 1130-5	8.9	79
57	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. *Journal of Neuro-Oncology*, **2010**, 99, 283-6	4.8	181
56	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. *Journal of Clinical Investigation*, **2009**, 119, 3000-10	15.9	268
55	KRAS mutations in non-small cell lung cancer. *Proceedings of the American Thoracic Society*, **2009**, 6, 201-5		399
54	Integration of molecular profiling into the lung cancer clinic. *Clinical Cancer Research*, **2009**, 15, 5317-22	12.9	73

53	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9435-40	11.5	196
52	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 18351-6	11.5	226
51	Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. *Clinical Cancer Research*, **2009**, 15, 5184-90	12.9	115
50	Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clinical Cancer Research*, **2009**, 15, 6790-9	12.9	139
49	PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. *Cancer Research*, **2009**, 69, 3256-61	10.1	411
48	Lung cancer in never smokers: molecular profiles and therapeutic implications. *Clinical Cancer Research*, **2009**, 15, 5646-61	12.9	122
47	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. *Journal of Clinical Oncology*, **2009**, 27, 6251-66	2.2	619
46	Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. *American Journal of Surgical Pathology*, **2009**, 33, 1752-64	6.7	179
45	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). *PLoS ONE*, **2009**, 4, e7273	3.7	109
44	Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 470-7	5	36
43	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. *Modern Pathology*, **2008**, 21 Suppl 2, S16-22	9.8	268
42	Somatic mutations affect key pathways in lung adenocarcinoma. *Nature*, **2008**, 455, 1069-75	50.4	2280
41	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *Journal of Clinical Oncology*, **2008**, 26, 1472-8	2.2	257
40	EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. *Journal of Molecular Diagnostics*, **2008**, 10, 242-8	5.1	149
39	Genetic predictors of MEK dependence in non-small cell lung cancer. *Cancer Research*, **2008**, 68, 9375-83	10.1	216
38	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. *Clinical Cancer Research*, **2008**, 14, 7519-25	12.9	227
37	Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. *Cancer Research*, **2008**, 68, 5524-8	10.1	185
36	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. *Clinical Cancer Research*, **2008**, 14, 5731-4	12.9	429

35	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. *Journal of Clinical Oncology*, **2008**, 26, 2745-53	2.2	222
34	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. *Clinical Cancer Research*, **2008**, 14, 7060-7	12.9	135
33	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. *Journal of Thoracic Oncology*, **2008**, 3, 111-6	8.9	224
32	EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. *Journal of Thoracic Oncology*, **2008**, 3, 805	8.9	16
31	Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. *Journal of Thoracic Oncology*, **2008**, 3, 84-93	8.9	24
30	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. *PLoS Medicine*, **2007**, 4, e294	11.6	252
29	Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. *PLoS ONE*, **2007**, 2, e426	3.7	73
28	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. *Cancer* , **2007**, 110, 599-605	6.4	91
27	Characterizing the cancer genome in lung adenocarcinoma. *Nature*, **2007**, 450, 893-8	50.4	900
26	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20932-7	11.5	1395
25	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. *Clinical Cancer Research*, **2007**, 13, 5150-5	12.9	252
24	Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. *PLoS ONE*, **2007**, 2, e810	3.7	93
23	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. *Journal of Clinical Investigation*, **2007**, 117, 3846-56	15.9	512
22	Defining clinically relevant molecular subsets of lung cancer. *Cancer Chemotherapy and Pharmacology*, **2006**, 58 Suppl 1, s11-5	3.5	16
21	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. *Cancer*, **2006**, 107, 1034-41	6.4	69
20	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 7232-41	12.9	315
19	Molecular on/off switch. *Journal of Clinical Oncology*, **2006**, 24, 4940-2	2.2	11
18	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clinical Cancer Research*, **2006**, 12, 839-44	12.9	597

17	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. *Genes and Development*, **2006**, 20, 1496-510	12.6	363
16	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clinical Cancer Research*, **2006**, 12, 6494-501	12.9	677
15	Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. *Journal of Clinical Oncology*, **2006**, 24, 1700-4	2.2	184
14	BAC Consensus Conference, November 4???6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. *Journal of Thoracic Oncology*, **2006**, 1, S2-S7	8.9	2
13	BAC Consensus Conference, November 4ﬀ, 2004: Epidemiology, Pathogenesis, and Preclinical Models. *Journal of Thoracic Oncology*, **2006**, 1, S2-S7	8.9	1
12	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. *Cancer Biology and Therapy*, **2005**, 4, 1096-7	4.6	4
11	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. *Journal of Molecular Diagnostics*, **2005**, 7, 396-403	5.1	200
10	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. *Journal of Clinical Oncology*, **2005**, 23, 2556-68	2.2	525
9	Practical management of patients with non-small-cell lung cancer treated with gefitinib. *Journal of Clinical Oncology*, **2005**, 23, 165-74	2.2	150
8	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Medicine*, **2005**, 2, e17	11.6	1160
7	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Medicine*, **2005**, 2, e73	11.6	2628
6	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 11011-6	11.5	487
5	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. *Clinical Cancer Research*, **2005**, 11, 7841-50	12.9	224
4	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13306-11	11.5	3659
3	QargetingQhe epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). *Seminars in Cancer Biology*, **2004**, 14, 33-40	12.7	55
2	Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2004**, 22, 1103-9	2.2	670
1	Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8764-9	11.5	53